Hosted on MSN
Recursion eyes breakthrough with REC-4881 drug for rare genetic condition, but shares pull back
Earlier this year, Recursion Pharmaceuticals Inc RXRX initiated discussions with the FDA for the design of a registrational study for its experimental drug REC-4881 in familial adenomatous polyposis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results